These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33339348)

  • 21. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis.
    Plachouri KM; Georgiou S
    Int J Dermatol; 2019 Sep; 58(9):1008-1013. PubMed ID: 30891751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.
    Nakamura M; Abrouk M; Farahnik B; Zhu TH; Bhutani T
    Cutis; 2018 Jan; 101(1):38;42;56. PubMed ID: 29529104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
    Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
    J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
    Brodmerkel C; Wadman E; Langley RG; Papp KA; Bourcier M; Poulin Y; Ho V; Guenther L; Kunynetz R; Nigen S; Vender R; Wasel N; Hsu MC; Szapary P
    J Drugs Dermatol; 2013 Oct; 12(10):1122-9. PubMed ID: 24085047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
    Takamura S; Sugai S; Taguchi R; Teraki Y
    J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Apremilast to Treat Psoriasis During Deployment.
    Rosenberg A; Meyerle J
    Mil Med; 2017 Jul; 182(7):1628-1631. PubMed ID: 28810954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccination status in psoriasis patients on immunosuppressant therapy (including biologics)].
    Bonhomme A; Fréling E; Reigneau M; Poreaux C; Valois A; Truchetet F; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2017 Feb; 144(2):92-99. PubMed ID: 27771122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations.
    Hall V; Johnson D; Torresi J
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 29635641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy.
    Bálint A; Farkas K; Éva PK; Terhes G; Urbán E; Szucs M; Nyári T; Bata Z; Nagy F; Szepes Z; Miheller P; Lorinczy K; Lakatos PL; Lovász B; Tamás S; Kulcsár A; Berényi A; Törocsik D; Daróczi T; Saródi Z; Wittmann T; Molnár T
    Scand J Gastroenterol; 2015 Feb; 50(2):174-81. PubMed ID: 25384624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythrodermic Psoriasis Treated with Apremilast.
    Arcilla J; Joe D; Kim J; Kim Y; Truong VN; Jaipaul N
    Dermatol Reports; 2016 Jun; 8(1):6599. PubMed ID: 27942369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.